Editas Medicine, Inc. Common StockEDIT

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institutes Cas12a patent estate and Broad Institute and Harvard Universitys Cas9 patent estates for human.

editasmedicine.com